GULP1 as a Downstream Effector of the Estrogen Receptor-β Modulates Cisplatin Sensitivity in Bladder Cancer

被引:0
作者
Tatenuma, Tomoyuki [1 ,2 ]
Matsukawa, Takuo [1 ,2 ]
Goto, Takuro [1 ,2 ]
Jiang, Guiyang [1 ,2 ]
Sharma, Adhya [1 ,2 ]
Najafi, Mohammad amin elahi [1 ,2 ]
Teramoto, Yuki [1 ,2 ]
Miyamoto, Hiroshi [1 ,2 ,3 ,4 ]
机构
[1] Univ Rochester, Med Ctr, Dept Pathol & Lab Med, 601 Elmwood Avenue,Box 626, Rochester, NY 14642 USA
[2] Univ Rochester, James P Wilmot Canc Inst, Med Ctr, Rochester, NY USA
[3] Univ Rochester, Med Ctr, Dept Urol, Rochester, NY USA
[4] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD USA
关键词
Bladder cancer; chemotherapy; cisplatin; estrogen receptor-beta; GULP1; ANDROGEN RECEPTOR; EXPRESSION;
D O I
10.21873/cgp.20472
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: Precise molecular mechanisms underlying resistance to cisplatin-based chemotherapy remain unclear, while the activity of estrogen receptor-/3 (ER/3) has been suggested to be associated with chemosensitivity in urothelial cancer. We aimed to determine if GULP1, an adapter protein known to facilitate phagocytosis, could represent a downstream effector of ER/3 and thereby modulate cisplatin sensitivity in bladder cancer. Materials and Methods: GULP1 expression and cisplatin cytotoxicity were compared in bladder cancer lines. Immunohistochemistry was used to determine the expression of GULP1 and ER/3 in two sets of tissue microarray (TMA) consisting of transurethral resection specimens. Results: The levels of GULP1 expression were considerably higher in ER/3- knockdown sublines than in the respective control ER/3-positive sublines. Estradiol treatment reduced GULP1 expression in ERa-negative/ER/3-positive lines, which was restored by the anti- estrogen tamoxifen. Chromatin immunoprecipitation assay revealed the binding of ER/3 to the GULP1 promoter in bladder cancer cells. Moreover, GULP1 knockdown sublines were significantly more resistant to cisplatin treatment, but not to other chemotherapeutic agents, including gemcitabine, methotrexate, vinblastine, and doxorubicin. In the first set of TMA (n=129), the expression of ER/3 and GULP1 was inversely correlated (p=0.023), and ER/3(-)/GULP1(+) in 51 muscle- invasive tumors was associated with significantly lower risk of disease progression and cancer-specific mortality. Similarly, in the second set (n=43), patients with ER/3(-)/GULP1(+) muscle- invasive disease were significantly (p=0.021) more likely to be responders to cisplatin-based neoadjuvant chemotherapy before radical cystectomy. Conclusion: ER/3 activation was found to reduce the expression of GULP1 as a direct downstream target in bladder cancer cells, resulting in the induction of cisplatin resistance.
引用
收藏
页码:557 / 565
页数:9
相关论文
共 50 条
  • [31] Neuroglobin overexpression induced by the 17-Estradiol-Estrogen receptor- Pathway reduces the sensitivity of MCF-7 Breast cancer cell to paclitaxel
    Fiocchetti, Marco
    Cipolletti, Manuela
    Leone, Stefano
    Ascenzi, Paolo
    Marino, Maria
    IUBMB LIFE, 2016, 68 (08) : 645 - 651
  • [32] FOXC1 is associated with estrogen receptor alpha and affects sensitivity of tamoxifen treatment in breast cancer
    Wang, Jinhua
    Xu, Yali
    Li, Li
    Wang, Lin
    Yao, Ru
    Sun, Qiang
    Du, Guanhua
    CANCER MEDICINE, 2017, 6 (01): : 275 - 287
  • [33] Inositol 1,4,5-trisphosphate (IP3) receptor type1 (IP3R1) modulates the acquisition of cisplatin resistance in bladder cancer cell lines
    Toshiyuki Tsunoda
    Hirofumi Koga
    Akira Yokomizo
    Katsunori Tatsugami
    Masatoshi Eto
    Junichi Inokuchi
    Akira Hirata
    Katsuaki Masuda
    Koji Okumura
    Seiji Naito
    Oncogene, 2005, 24 : 1396 - 1402
  • [34] Recruited T cells promote the bladder cancer metastasis via up-regulation of the estrogen receptor β/1L-1/c-MET signals
    Tao, Le
    Qiu, Jianxin
    Slavin, Spencer
    Ou, Zhenyu
    Liu, Zhihong
    Ge, Jifu
    Zuo, Li
    Guancial, Elizabeth A.
    Messing, Edward M.
    Chang, Chawnshang
    Yeh, Shuyuan
    CANCER LETTERS, 2018, 430 : 215 - 223
  • [35] The PAPSS1 gene is a modulator of response to cisplatin by regulating estrogen receptor alpha signaling activity in ovarian cancer cells
    Sun, Lei
    Ji, Wei-Xue
    Li, Yan
    Li, Ze-Lian
    Duan, Can-Can
    Xia, Bai-rong
    Xiao, Lan
    JOURNAL OF OVARIAN RESEARCH, 2023, 16 (01)
  • [36] WP1130 increases cisplatin sensitivity through inhibition of usp9x in estrogen receptor-negative breast cancer cells
    Fu, Peifen
    Du, Feiya
    Liu, Yu
    Yao, Minya
    Zhang, Shufeng
    Zheng, Xiaoxiao
    Zheng, Shusen
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2017, 9 (04): : 1783 - 1791
  • [37] Senescence-related gene c-Myc affects bladder cancer cell senescence by interacting with HSP90B1 to regulate cisplatin sensitivity
    Wang, Yaxuan
    Zhu, Haixia
    Xu, Haifei
    Qiu, Yifan
    Zhu, Yonghong
    Wang, Xiaolin
    AGING-US, 2023, 15 (15): : 7408 - 7423
  • [38] RHBDF1 modulates cisplatin sensitivity of small cell lung cancer through YAP1/Smad2 signaling pathway
    Wang, Lei
    Qi, Lishuang
    Huang, Xiaoyi
    Feng, Xiao
    Gan, Junqing
    Zhang, Juxuan
    Xi, Yuhui
    Zhang, Shuai
    Meng, Qingwei
    HELIYON, 2024, 10 (13)
  • [39] Downregulation of microRNA-515-5p by the Estrogen Receptor Modulates Sphingosine Kinase 1 and Breast Cancer Cell Proliferation
    Pinho, Filipa G.
    Frampton, Adam E.
    Nunes, Joao
    Krell, Jonathan
    Alshaker, Heba
    Jacob, Jimmy
    Pellegrino, Loredana
    Roca-Alonso, Laura
    de Giorgio, Alexander
    Harding, Victoria
    Waxman, Jonathan
    Stebbing, Justin
    Pchejetski, Dmitry
    Castellano, Leandro
    CANCER RESEARCH, 2013, 73 (19) : 5936 - 5948
  • [40] Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-α and survivin
    Vanderlaag, Kathryn E.
    Hudak, Susan
    Bald, Laura
    Fayadat-Dilman, Laurence
    Sathe, Manjiri
    Grein, Jeff
    Janatpour, Mary J.
    BREAST CANCER RESEARCH, 2010, 12 (03)